An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

Trial Profile

An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Kura Oncology
  • Most Recent Events

    • 25 Jun 2017 Preliminary results (n=18, data cut off: 2/15/2017) presented at the 22nd Congress of the European Haematology Association
    • 07 Jun 2017 According to a Kura Oncology media release, data from this trial will be presented at 14th International Conference on Malignant Lymphoma (ICML).
    • 15 May 2017 Data from this trial will be presented at the European Hematology Association Conference 2017, according to a Kura Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top